vs
Side-by-side financial comparison of ASHLAND INC. (ASH) and Orla Mining Ltd. (ORLA). Click either name above to swap in a different company.
ASHLAND INC. is the larger business by last-quarter revenue ($386.0M vs $251.2M, roughly 1.5× Orla Mining Ltd.).
Ashland, Inc., is an American chemical company headquartered in Wilmington, Delaware. The company began as an oil refinery in the city of Ashland, Kentucky, in 1924, before moving to Wilmington in 1994. The company has five wholly owned divisions, which include Chemical Intermediates and Solvents, composites, industrial specialties, personal and home care, pharmaceuticals, food and beverage, and agriculture. Until 2017, the company was the primary manufacturer of Valvoline.
Orla Mining Ltd. is a Canada-based mineral exploration and development firm focused on high-grade gold and precious metal assets in North and Central America, with core projects in Mexico and Nevada, U.S. It follows sustainable responsible mining practices, collaborates with local communities, and delivers long-term value to stakeholders.
ASH vs ORLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $386.0M | $251.2M |
| Net Profit | $-12.0M | — |
| Gross Margin | 27.2% | — |
| Operating Margin | -1.6% | — |
| Net Margin | -3.1% | — |
| Revenue YoY | -4.7% | — |
| Net Profit YoY | 92.7% | — |
| EPS (diluted) | $-0.26 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $386.0M | — | ||
| Q3 25 | $477.0M | $251.2M | ||
| Q2 25 | $463.0M | $151.8M | ||
| Q1 25 | $479.0M | — | ||
| Q4 24 | $405.0M | — | ||
| Q3 24 | $521.0M | $584.4M | ||
| Q2 24 | $544.0M | $110.4M | ||
| Q1 24 | $575.0M | — |
| Q4 25 | $-12.0M | — | ||
| Q3 25 | $31.0M | — | ||
| Q2 25 | $-742.0M | — | ||
| Q1 25 | $31.0M | — | ||
| Q4 24 | $-165.0M | — | ||
| Q3 24 | $17.0M | $-368.9M | ||
| Q2 24 | $6.0M | — | ||
| Q1 24 | $120.0M | — |
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | — | ||
| Q2 24 | 34.2% | — | ||
| Q1 24 | 28.0% | — |
| Q4 25 | -1.6% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | -152.9% | — | ||
| Q1 25 | 10.6% | — | ||
| Q4 24 | -44.2% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | -11.2% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | -3.1% | — | ||
| Q3 25 | 6.5% | — | ||
| Q2 25 | -160.3% | — | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | -40.7% | — | ||
| Q3 24 | 3.3% | -63.1% | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 20.9% | — |
| Q4 25 | $-0.26 | — | ||
| Q3 25 | $0.83 | — | ||
| Q2 25 | $-16.21 | — | ||
| Q1 25 | $0.65 | — | ||
| Q4 24 | $-3.50 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.12 | — | ||
| Q1 24 | $2.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $304.0M | — |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $1.9B | $507.4M |
| Total Assets | $4.5B | $598.3M |
| Debt / EquityLower = less leverage | 0.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $304.0M | — | ||
| Q3 25 | $215.0M | — | ||
| Q2 25 | $207.0M | — | ||
| Q1 25 | $168.0M | — | ||
| Q4 24 | $219.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $399.0M | $96.6M | ||
| Q1 24 | $439.0M | — |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $507.4M | ||
| Q2 25 | $1.9B | $507.4M | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.9B | $968.6M | ||
| Q2 24 | $3.0B | $400.5M | ||
| Q1 24 | $3.1B | — |
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.6B | $598.3M | ||
| Q2 25 | $4.6B | $598.3M | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.2B | — | ||
| Q3 24 | $5.6B | $1.3B | ||
| Q2 24 | $5.7B | $535.8M | ||
| Q1 24 | $5.9B | — |
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $125.0M | $126.9M |
| Free Cash FlowOCF − Capex | $111.0M | — |
| FCF MarginFCF / Revenue | 28.8% | — |
| Capex IntensityCapex / Revenue | 3.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $200.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $125.0M | — | ||
| Q3 25 | $40.0M | $126.9M | ||
| Q2 25 | $115.0M | $74.9M | ||
| Q1 25 | $9.0M | — | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $80.0M | $92.4M | ||
| Q2 24 | $127.0M | $22.4M | ||
| Q1 24 | $54.0M | — |
| Q4 25 | $111.0M | — | ||
| Q3 25 | $6.0M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $-12.0M | — | ||
| Q4 24 | $-53.0M | — | ||
| Q3 24 | $42.0M | — | ||
| Q2 24 | $98.0M | — | ||
| Q1 24 | $20.0M | — |
| Q4 25 | 28.8% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 20.5% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | -13.1% | — | ||
| Q3 24 | 8.1% | — | ||
| Q2 24 | 18.0% | — | ||
| Q1 24 | 3.5% | — |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 5.3% | — | ||
| Q1 24 | 5.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
ORLA
Segment breakdown not available.
